Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prevagen Study Data Withstand False Ad Complaint By FTC, New York AG

Executive Summary

A federal judge dismissed a complaint filed by FTC and New York AG Schneiderman against Quincy Biosciences about claims for Prevagen cognitive supplement. The complaint did not show the company violated the FTC Act because it pointed only to possible errors in a supporting study.


Related Content

Dietary Supplement Sector Warnings Jump With FDA 'Program Alignment'
New York AG And FTC Target Prevagen Memory Claims
Supplement Claims For Autism Treatment Could Ring A Bell At FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts